Mapping the global landscape of artificial intelligence in pancreatic cancer research: A bibliometric and visualization analysis.

Authors

Pegah Rashidian, Aseel Smerat, Mohammad Ahmar Khan, Pankaj Bansal, Chandan Sharma, Djaloliddin Mansurov, Seyedsina Moghimnejadhosseini, Amirmahdi Mojtahedzadeh, Mahsa Talebzadeh, Ehsan Amini-Salehi

Published in

Medicine. Volume 105. Issue 39. Pages e50681. Sep 25, 2026.

Abstract

Artificial intelligence (AI) applications in pancreatic cancer are expanding rapidly, but the field's global structure and emerging priorities remain incompletely characterized.
The Web of Science Core Collection was searched through July 5, 2026. English-language original articles and reviews addressing AI in pancreatic cancer were eligible. After manual screening, 583 publications from 1998 to 2026 were analyzed using Biblioshiny, VOSviewer, and CiteSpace to assess publication trends, contributors, collaboration networks, co-citation patterns, keyword evolution, thematic clusters, and citation bursts.
Publication output accelerated after 2019 and reached 164 publications in 2025; the lower total in 2026 reflected partial-year coverage. The literature involved 59 countries, 1230 institutions, and 4038 authors. China produced the largest number of publications (n = 222), whereas the United States ranked second (n = 150) and had the highest country-level centrality (0.39). Shanghai Jiao Tong University was the most productive institution (n = 20), while Harvard University had the highest institutional centrality (0.22). Frontiers in Oncology was the most productive journal (n = 32). Influential studies focused on deep learning-based computed tomography, electronic health record-based risk prediction, exosome-based machine learning, and endoscopic ultrasonography. Research themes evolved from neural-network classification and texture analysis toward radiomics, deep learning, early detection, risk prediction, liquid biopsy, tumor biology, treatment-response prediction, and precision oncology.
AI research in pancreatic cancer is growing rapidly and becoming increasingly multidisciplinary, although productivity and collaboration remain uneven. Clinical translation will require prospective multicenter validation, representative datasets, transparent reporting, calibration, fairness assessment, workflow evaluation, and evidence of improved patient outcomes.

PMID:
42798094
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.